Exercise completion of 450,000 stock acquisition rights. Includes details on issued shares, number of stock acquisition rights, exercise date, and the counterparty\u2019s name.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4596","jir_company_name":"Kubota Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4596-20260707-01.pdf","jir_short_summary":"Exercise completion of 450,000 stock acquisition rights. Includes details on issued shares, number of stock acquisition rights, exercise date, and the counterparty\u2019s name.","jir_summary":"### Overview\nKubota Pharmaceutical Holdings Co., Ltd. announced the completion of the exercise of the 38th stock acquisition rights. The notice includes the name of the stock acquisition rights, the number issued, and the exercise date; counterparties\u2019 name and exercise conditions are described in the body of the notice.\n\n### Impact going forward\nTo assess changes in capital structure and potential dilution and progress of capital policy, refer to the figures described in the body. In future disclosures, remaining rights and changes in exercise conditions may arise.","jir_financial_highlights":"Number of stock acquisition rights issued for this: 450,000 shares (Unknown)\nIssue date of this stock acquisition rights: December 22, 2025 (Unknown)\nName of stock acquisition rights: This Stock Acquisition Rights (EVO FUND ) (Unknown)","jir_category":"","jir_hashtags":"#KubotaPharmaceuticalHoldings, #StockAcquisitionRights, #CapitalPolicy","jir_key_figures":"Number of stock acquisition rights issued: 450,000 shares\nIssue date of stock acquisition rights: 2025-12-22\nName of stock acquisition rights: EVO FUND","jir_meta_title":"Kubota Pharmaceutical Holdings \u2013 Announcement of stock acquisition rights exercise completion | 450,000 shares | 2025-12-22","jir_meta_description":"Kubota Pharmaceutical Holdings announces the completion of the exercise of stock acquisition rights through a third-party allotment. Summary of issued quantity, exercise date, and rights name for investors.","jir_og_title":"Kubota Pharmaceutical Holdings \u2013 Exercise completion of stock acquisition rights announced","jir_og_description":"Announcement of completion of exercise for 450,000 stock acquisition rights. Key points: issue date, name, and impact on capital policy.","jir_og_image_url":"\/assets\/og\/company-tender_offer.jpg","jir_chart_data_collection":"[]","ir_related_company":59981,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"tender_offer","footnotes":""},"sector":[],"importance":[],"class_list":["post-76994","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n